PARECOXIB FOR INJECTION

Founded in 2002, Shanghai Chenpon Pharmaceutical Co., Ltd. (chenpon.com) manufactures, exports and imports finished-dose pharmaceutical products from its Shanghai base. Its portfolio spans a wide therapeutic range, including ubenimex tablets, valacyclovir hydrochloride, cefprozil dispersible tablets, carbamazepine and primidone tablets, fluoxetine hydrochloride capsules, losartan potassium tablets, lansoprazole and omeprazole for injection, mosapride citrate capsules, parecoxib for injection, and respiratory products such as budesonide-formoterol inhalation powder and fluticasone suspension, categorized across anti-tumor, antibiotic/antiviral, nervous system, cardiovascular, digestive, urinary/reproductive, analgesic and respiratory drug classes. The company promotes its own brand, internationally certified manufacturing, experienced R&D personnel, production capacity, CRO/CMO contract customization and a broad product line, selling into North and South America, Western and Eastern Europe, Australasia, Asia, the Middle East and Africa.